Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 23;33(5):545–558. doi: 10.1177/1945892419850924

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Pooled analysis of subgroup factor effect on subjective and objective outcomes at day 90. The changes from baseline to day 90 in symptomatic and endoscopic outcomes across subgroups based on analysis of the pooled data from 2 RCTs, totaling 375 patients with NP grade ≥ 2 on each side at screening who were indicated for RESS, are shown. The treatment group underwent in-office bilateral placement of MF sinus implants, and the control group underwent a sham procedure. All patients (treatment and control) were required to use MFNS once daily. Summary statistics include estimates of the treatment effect (mean difference or odds ratio between treatment groups, 95% CI) within subgroups, the overall treatment effect when accounting for subgroups effect, and the interaction of treatment by subgroup. Subgroups representing <10% of ITT population were omitted. Treatment effects with P < .05 were considered statistically significant and are highlighted in bold font and with blue shaded diamonds. A, Change in NO/C score (scale 0–3, with higher scores indicating greater severity). B, Change in mean BPG (scale 0–8, with higher scores indicating greater severity), as determined based on a centralized blinded video-endoscopy review by an independent panel of 3 sinus surgeons. C, Change in ESO (VAS 0–100, with higher scores indicating greater severity), as determined by the independent panel. D, Proportion of patients still indicated for RESS. AERD, aspirin-exacerbated respiratory disease; CI, confidence interval; ESO, ethmoid sinus obstruction; ESS, endoscopic sinus surgery; ITT, intent-to-treat; MF, mometasone furoate; MFNS, MF nasal spray; n/a, not applicable; NO/C, nasal obstruction/congestion; NP, nasal polyps; RCT, randomized controlled trial; RESS, revision ESS; VAS = visual analog scale.

Figure 3. — Pooled analysis of subgroup factor effect on subjective and objective outcomes at day 90. The changes from baseline to day 90 in symptomatic and endoscopic outcomes across subgroups based on analysis of the pooled data from 2 RCTs, totaling 375 patients with NP grade ≥ 2 on each side at screening who were indicated for RESS, are shown. The treatment group underwent in-office bilateral placement of MF sinus implants, and the control group underwent a sham procedure. All patients (treatment and control) were required to use MFNS once daily. Summary statistics include estimates of the treatment effect (mean difference or odds ratio between treatment groups, 95% CI) within subgroups, the overall treatment effect when accounting for subgroups effect, and the interaction of treatment by subgroup. Subgroups representing <10% of ITT population were omitted. Treatment effects with P < .05 were considered statistically significant and are highlighted in bold font and with blue shaded diamonds. A, Change in NO/C score (scale 0–3, with higher scores indicating greater severity). B, Change in mean BPG (scale 0–8, with higher scores indicating greater severity), as determined based on a centralized blinded video-endoscopy review by an independent panel of 3 sinus surgeons. C, Change in ESO (VAS 0–100, with higher scores indicating greater severity), as determined by the independent panel. D, Proportion of patients still indicated for RESS. AERD, aspirin-exacerbated respiratory disease; CI, confidence interval; ESO, ethmoid sinus obstruction; ESS, endoscopic sinus surgery; ITT, intent-to-treat; MF, mometasone furoate; MFNS, MF nasal spray; n/a, not applicable; NO/C, nasal obstruction/congestion; NP, nasal polyps; RCT, randomized controlled trial; RESS, revision ESS; VAS = visual analog scale.